Researchers at Sanford Burnham Prebys unveiled DeepTarget, a machine‑learning platform published in npj Precision Oncology that predicts anti‑cancer mechanisms of small molecules by integrating molecular signatures and systems biology. The tool challenges one‑drug/one‑target assumptions and identifies probable on‑ and off‑targets, suggesting mechanisms that can guide preclinical experiments and repurposing. DeepTarget aims to accelerate target deconvolution and reduce costly blind lead optimization steps by prioritizing likely mechanisms and biomarker hypotheses for follow‑up. The approach supports hypothesis‑driven experiments and could improve translational decisions in small‑molecule oncology discovery.